PT  - JOURNAL ARTICLE
AU  - Satoshi Muraoka
AU  - Annina M. DeLeo
AU  - Manveen K. Sethi
AU  - Kayo Yukawa-Takamatsu
AU  - Zijian Yang
AU  - Jina Ko
AU  - John D. Hogan
AU  - Zhi Ruan
AU  - Yang You
AU  - Yuzhi Wang
AU  - Maria Medalla
AU  - Seiko Ikezu
AU  - Weiming Xia
AU  - Santi Gorantla
AU  - Howard E. Gendelman
AU  - David Issadore
AU  - Joseph Zaia
AU  - Tsuneya Ikezu
TI  - Proteomic and Biological Profiling of Extracellular Vesicles from Alzheimer’s Disease Human Brain Tissues
AID  - 10.1101/733477
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 733477
4099  - http://biorxiv.org/content/early/2019/08/15/733477.short
4100  - http://biorxiv.org/content/early/2019/08/15/733477.full
AB  - Introduction Extracellular vesicles (EVs) from human Alzheimer’s disease (AD) biospecimens contain amyloid-β peptide (Aβ) and tau. While AD EVs are known to affect brain disease pathobiology, their biochemical and molecular characterizations remain ill defined.Methods EVs were isolated from the cortical grey matter of 20 AD and 18 control brains. Tau and Aβ levels were measured by immunoassay. Differentially expressed EV proteins were assessed by quantitative proteomics and machine learning.Results Levels of pS396 tau and Aβ were significantly elevated in AD EVs. High levels of neuron- and glia- specific factors are detected in control and AD EVs, respectively. Machine learning identified ANXA5, VGF, GPM6A and ACTZ in AD EV compared to controls. They distinguished AD EVs from controls in the test sets with 88% accuracy.Discussion In addition to Aβ and tau, ANXA5, VGF, GPM6A and ACTZ are new signature proteins in AD EVs.